208 related articles for article (PubMed ID: 17162210)
1. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading.
Sale GE; Deeg HJ; Porter BA
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1285-94. PubMed ID: 17162210
[TBL] [Abstract][Full Text] [Related]
2. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
Kerbauy DM; Gooley TA; Sale GE; Flowers ME; Doney KC; Georges GE; Greene JE; Linenberger M; Petersdorf E; Sandmaier BM; Scott BL; Sorror M; Stirewalt DL; Stewart FM; Witherspoon RP; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
5. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
6. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
8. [Complete regression of bone marrow fibrosis following allogeneic peripheral blood stem cell transplantation in a patient with idiopathic myelofibrosis].
Benesová P; Dĕdic K; Zák P; Voglová J
Cesk Patol; 2004 Oct; 40(4):167-71. PubMed ID: 15645853
[TBL] [Abstract][Full Text] [Related]
9. Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.
Courcoutsakis N; Spanoudaki A; Maris TG; Astrinakis E; Spanoudakis E; Tsatalas C; Prassopoulos P
J Magn Reson Imaging; 2012 Mar; 35(3):696-702. PubMed ID: 22069235
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.
Thiele J; Kvasnicka HM; Dietrich H; Stein G; Hann M; Kaminski A; Rathjen N; Metz KA; Beelen DW; Ditschkowski M; Zander A; Kroeger N
Histol Histopathol; 2005 Jul; 20(3):879-89. PubMed ID: 15944939
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and myelofibrosis: correlation of MR imaging, clinical, and laboratory findings.
Kaplan KR; Mitchell DG; Steiner RM; Murphy S; Vinitski S; Rao VM; Burk DL; Rifkin MD
Radiology; 1992 May; 183(2):329-34. PubMed ID: 1561331
[TBL] [Abstract][Full Text] [Related]
12. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis.
Poulsen LW; Melsen F; Bendix K
APMIS; 1998 Apr; 106(4):495-9. PubMed ID: 9637273
[TBL] [Abstract][Full Text] [Related]
13. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
14. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
15. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
[TBL] [Abstract][Full Text] [Related]
17. Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N; Mesa RA
Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
[TBL] [Abstract][Full Text] [Related]
18. Reversal of severe bone marrow fibrosis and osteosclerosis following allogeneic bone marrow transplantation for chronic granulocytic leukaemia.
McGlave PB; Brunning RD; Hurd DD; Kim TH
Br J Haematol; 1982 Oct; 52(2):189-94. PubMed ID: 6751377
[TBL] [Abstract][Full Text] [Related]
19. The impact of bone marrow fibrosis on the outcome of hematopoietic stem cell transplantation.
Suyanı E; Akı SZ; Yegin ZA; Ozkurt ZN; Altındal S; Akyürek N; Yaǧcı M; Sucak GT
Transplant Proc; 2010 Sep; 42(7):2713-9. PubMed ID: 20832575
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell transplantation for chronic myeloproliferative disorders.
Tse W; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2006; 54(6):375-80. PubMed ID: 17122883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
